BioTime announced that its subsidiary Cell Cure Neurosciences has been awarded a grant of 5 million NIS (approximately $1.33 million) from Israel’s Office of the Chief Scientist. The funds will help finance the development of OpRegen(R), a cell-based therapeutic product for the treatment of age-related macular degeneration – a severe form of acute vision loss and the leading cause of blindness in an aging population. Cell Cure, established in 2005 is located in Jerusalem, Israel on the campus of Hadassah University Hospital.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024

TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024

Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024

BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments